A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk

被引：0
|
作者：
Choueiri, Toni K.
Albiges, Laurence
Powles, Thomas
Scheffold, Christian
Wang, Fong
Motzer, Robert J.
机构：
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Queen Mary Univ London, Barts Canc Inst, London, England
[5] Exelixis Inc, Alameda, CA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS767
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    McDermott, D. F.
    Infante, J. R.
    Chowdhury, S.
    Voss, M. H.
    Motzer, R. J.
    Perini, R. F.
    Morosky, A.
    Zheng, F. F.
    White, B. C.
    Wang, Q.
    Jewell, R. C.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S519 - S520
  • [42] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
    Bourlon, Maria Teresa
    Escudier, Bernard
    Burotto, Mauricio
    Powles, Thomas
    Apolo, Andrea B.
    Shah, Amishi Yogesh
    Porta, Camillo
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    Wang, Fong
    Wang, Peter
    Panzica, Julie
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 362 - 362
  • [43] An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
    Ahrens, M.
    Escudier, B.
    Haanen, J. B. A. G.
    Boleti, E.
    Goupil, Gross M.
    Grimm, M. O.
    Negrier, S.
    Barthelemy, P.
    Gravis, G.
    Ivany, P.
    Bedke, J.
    Castellano, D.
    Panic, A.
    Mellado, B.
    Maroto, J. P.
    Roten, S.
    Zschaebitz, S.
    Deckbar, D.
    Hartmann, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 74 - 75
  • [44] An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
    Ahrens, Marit
    Escudier, Bernard
    Haanen, John
    Boleti, Ekaterini
    Gross-Goupil, Marine
    Grimm, Marc-Oliver
    Negrier, Sylvie
    Barthelemy, Philippe
    Gravis, Gwenaelle
    Ivanyi, Philipp
    Bedke, Jens
    Castellano, Daniel
    Panic, Andrej
    Mellado, Begona
    Maroto, Pablo
    Rottey, Sylvie
    Zschaebitz, Stefanie
    Floercken, Anne
    Boegemann, Martin
    Waddell, Tom
    Rodriguez, Cristina Suarez
    Lorch, Anja
    Deckbar, Dorothee
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 101 - 102
  • [45] QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK
    Shah, R.
    Botteman, M.
    Kwon, Y.
    Gooden, K. M.
    Cella, D.
    Motzer, R.
    VALUE IN HEALTH, 2019, 22 : S106 - S106
  • [46] A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Chowdhury, Simon
    McDermott, David F.
    Voss, Martin Henner
    Hawkins, Robert E.
    Aimone, Paola
    Voi, Maurizio
    Isabelle, Naeije
    Wu, Vi
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
    McDermott, David F.
    Motzer, Roberti.
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Sznol, Mario
    George, Saby
    Drake, Charles G.
    Rini, Brian I.
    Choueiri, Toni K.
    Kuzel, Timothy
    Sosman, Jeffrey Alan
    Smith, David C.
    Vaishampayan, Ulka N.
    Powderly, John D.
    Topalian, Suzanne Louise
    Zhao, Huanyu
    Waxman, Ian M.
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.
    Agarwal, Ruchi
    Ebrahimi, Hedyeh
    Zengin, Zeynep Busra
    Carrillo, Regina Barragan
    Dizman, Nazli
    Zugman, Miguel
    Jaime-Casas, Salvador
    Meza, Luis A.
    Li, Xiaochen
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin
    Lee, Peter P.
    Takahashi, Motomichi
    Tripathi, Abhishek
    Dorff, Tanya B.
    Caporaso, Gregory
    Lee, Keehoon
    Pal, Sumanta Kumar
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS611 - TPS611
  • [49] Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study
    Basso, U.
    Paolieri, F.
    Porta, C. G.
    De Giorgi, U.
    Bracarda, S.
    Antonuzzo, L.
    Atzori, F.
    Carteni, G.
    Procopio, G.
    Fratino, L.
    D'Arcangelo, M.
    Fornarini, G.
    Zucali, P. A.
    Cusmai, A.
    Santoni, M.
    Baldessari, C.
    Naglieri, E.
    Panni, S.
    Zagonel, V.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S566 - S566
  • [50] Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naive advanced renal cell carcinoma (RCC)
    Agarwal, N.
    Vaishampayan, U.
    Green, M.
    di Nucci, F.
    Chang, P-Y.
    Scheffold, C.
    Pal, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 308 - 308
12345